Argatroban: A direct thrombin inhibitor with reliable and predictable anticoagulant actions

Drugs of Today

Volumn 42, Issue 4, 2006, Pages 223-236

  Escolar, Ginés ^a,c   Bozzo, Jordi ^b   Maragall, Santiago ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b PROUS SCIENCE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; DK 7419; GN 1600; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; THROMBIN INHIBITOR;

ANTICOAGULATION; ARTERY OCCLUSION; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; EXPERIMENTAL MODEL; HEART INFARCTION; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; NONHUMAN; REVIEW; STROKE; THROMBOEMBOLISM; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CEREBROVASCULAR ACCIDENT; DRUG MONITORING; HUMANS; INTRACRANIAL THROMBOSIS; PIPECOLIC ACIDS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBIN; THROMBOCYTOPENIA;

EID: 33745134060     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.4.953588     Document Type: Review

References (85)

1. MacFarlane, R.G. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964, 202: 498-9.
2. Davie, E.W., Ratnoff, O.D. Waterfall sequence for intrinsic blood clotting. Science 1964, 145: 1310-2.
3. Hoffman, M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003, 17 (Suppl. 1): S1-S5.
4. Weiss, H.J., Turitto, V.T., Baumgartner, H.R., Nemerson, Y., Hoffmann, T. Evidence for the presence of tissue factor activity on subendothelium. Blood 1989, 73: 968-75.
5. Fuster, V., Badimon, L., Badimon, J.J., Chesebro, J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl J Med 1992, 326: 242-50.
6. Toschi, V., Gallo, R., Lettino, M. et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997, 95: 594-9.
7. Kroegel, C., Reissig, A. Principle mechanisms underlying venous thromboembolism: Epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003, 70: 7-30.
8. Giesen, P.A., Rauch, U., Bohrmann, B. et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999, 96: 2311-5.
9. Rauch, U., Nemerson, Y. Circulating tissue factor and thrombosis. Curr Opin Hematol 2000, 7: 273-7.
10. Muller, I., Klocke, A., Alex, M. et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003, 17: 476-8.
11. Lopez, J.A., Kearon, C., Lee, A.Y. Deep venous thrombosis. Hematology 2004, 2004, 1: 439-56.
12. Okamoto, S., Hijikata, A., Kinjoh, K. et al. A novel series of synthetic thrombin-inhibitors having extremely potent and highly selective action. Kobe J Med Sci 1975, 21: 43-51.
13. Nutescu, E.A., Wittkowsky, A.K. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004, 38: 99-109.
14. Warkentin, T.E., Kelton, J.G. Heparin-induced thrombocytopenia. Principles of Transfusion Medicine 1990, 1-34.
15. Warkentin, T.E., Kelton, J.G. Heparin and platelets. Hematol Oncol Clin North Am 1990, 4: 243-64.
16. Kelton, J.G. The clinical management of heparin-induced thrombocytopenia. Semin Hematol 1999, 36: 17-21.
17. Chong, B.H. Heparin-induced thrombocytopenia. J Thromb Haemost 2003, 1: 1471-8.
18. Brieger, D.B., Mak, K.H., Kottke-Marchant, K., Topol, E.J. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998, 31: 1449-59.
19. King, D.J., Kelton, J.G. Heparin-associated thrombocytopenia. Ann Intern Med 1984, 100: 535-40.
20. Nicolaides, A.N. Clinical results with direct thrombin inhibitors. Pathophysiol Haemost Thromb 2002, 32 (Suppl. 3): 36-8.
21. Kaplan, K.L., Francis, C.W. Direct thrombin inhibitors. Semin Hematol 2002, 39: 187-96.
22. Eichler, P., Friesen, H. J., Lubenow, N., Jaeger, B., Greinacher, A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance. Blood 2000, 96: 2373-78.
23. Greinacher, A., Eichler, P., Albrecht, D., Strobel, U., Potzsch, B., Eriksson, B.I. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: Incidence and clinical relevance. Blood 2003, 101: 2617-9.
24. Eichler, P., Lubenow, N., Strobel, U., Greinacher, A. Antibodies against lepirudin are poly-specific and recognize epitopes on bivalirudin. Blood 2004, 103: 613-6.
25. Okamoto, S., Hijikata, A., Kikumoto, R. et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981, 101: 440-6.
26. Kikumoto, R., Tamao, Y., Tezuka, T. et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidine-carboxylic acid. Biochemistry 1984, 23: 85-90.
27. Banner, D.W., Hadvary, P. Inhibitor binding to thrombin: X-ray crystallographic studies. Adv Exp Med Biol 1993, 340: 27-33.
28. Bauer, M., Brandstetter, H., Turk, D., Sturzebecher, J., Bode, W. Crystallographic determination of thrombin complexes with small synthetic inhibitors as a starting point for the receptor-based design of antithrombotics. Semin Thromb Hemost 1993, 19: 352-60.
29. Berry, C.N., Girardot, C., Lecoffre, C., Lunven, C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb Haemost 1994, 72: 381-6.
30. Walenga, J.M. An overview of the direct thrombin inhibitor argatroban. Pathophysiol Haemost Thromb 2002, 32 (Suppl. 3): 9-14.
31. Berry, C.N., Girard, D., Lochot, S., Lecoffre, C. Antithrombotic actions of argatroban in rat models of venous 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994, 113: 1209-14.
32. Hantgan, R.R., Jerome, W.G., Hursting, M.J. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood 1998, 92: 2064-74.
33. Fitzgerald, D., Murphy, N. Argatroban: A synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996, 7: 455-8.
34. Verstraete, M. Modulating platelet function with selective thrombin inhibitors. Haemostasis 1996, 26 (Suppl. 4): 70-7.
35. Czervionke, R.L., Hoak, J.C., Haycraft, D.L., Fry, G.L. Inhibition of thrombin-induced platelet adherence to vascular cells by synthetic thrombin inhibitor No. 805. Trans Assoc Am Physicians 1983, 96: 271-7.
36. Callas, D.D., Hoppensteadt, D., Fareed, J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin. Semin Thromb Hemost 1995, 21: 177-83.
37. Izawa, O., Katsuki, M., Komatsu, T., Iida, S. Pharmacokinetic studies of argipidine (MD-805) in human - Concentrations of argipidine and its metabolites in plasma, urine and feces during and after drip intravenous infusion. Jpn Pharmacol Ther 1986, 14 (Suppl. 5): 251-63.
38. Verstraete, M. Direct thrombin inhibitors: Appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997, 78: 357-63.
39. Tomoda, H. Experimental evaluation of coronary thrombodynamics and effects of pharmacological interventions in acute coronary syndromes. Jpn Circ J 1992, 56: 1184-90.
40. Morishita, K., Wada, M., Kumada, T., Tanaka, T., Tomikawa, M., Iwamoto, M. Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats. Thromb Res 1991, 63: 373-84.
41. Callas, D.D., Iqbal, O., Hoppensteadt, D., Fareed, J. Fibrinolytic compromise by synthetic and recombinant thrombin inhibitors: Implications in the treatment of thrombotic disorders. Clin Appl Thromb/Hemost 1995, 1: 114-24.
42. Berry, C.N., Girard, D., Girardot, C., Lochot, S., Lunven, C., Visconte, C. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit. Semin Thromb Hemost 1996, 22: 233-41.
43. Hara, H., Tamao, Y., Kikumoto, R., Okamoto, S. Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits. Thromb Haemost 1987, 57: 165-70.
44. Maekawa, I. Clinical evaluation of synthetic thrombin inhibitor MD-805 in disseminated intravascular coagulation (DIC). Therapeutic Research 1987, 6: 409-17.
45. Nagasawa, H., Fukutake, K., Hada, M. Phase one study of synthetic antithrombin agent (MD-805) single and multiple administration studies. Jpn J Clin Pharmacol Ther 1981, 12: 359-75.
46. Swan, S.K., Hursting, M.J. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000, 20: 318-29.
47. Walenga, J.M., Ahmad, S., Hoppensteadt, D., Iqbal, O., Hursting, M.J., Lewis, B.E. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002, 105: 401-5.
48. Ahmad, S., Ahsan, A., George, M. et al. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications. Clin Appl Thromb Hemost 1999, 5: 252-8.
49. Tatsuno, J., Komatsu, T., Iida, S. Pharmacokinetic studies of argatroban (MD-805): Protein binding and blood cell binding. Jap Pharmacol Ther 1986, 14 (Suppl. 5): 243-9.
50. Kondo, L.M., Wittkowsky, A.K., Wiggins, B.S. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann Pharmacother 2001, 35: 440-51.
51. Verme-Gibboney, C.N., Hursting, M.J. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2003, 37: 970-5.
52. Swan, S.K., St Peter, J.V., Lambrecht, L.J., Hursting, M.J. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000, 20: 756-70.
53. Tran, J.Q., Di Cicco, R.A., Sheth, S.B. et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999, 39: 513-9.
54. Argatroban prescribing information, Texas Biotechnology Corporation and GlaxoSmithKline. Available at http://www argatroban com/2005
55. Fareed, J., Jeske, W.P. Small-molecule direct antithrombins: Argatroban. Best Pract Res Clin Haematol 2004, 17: 127-38.
56. Ikoma, H. Development of argatroban as an anticoagulant and antithrombin agent in Japan. Pathophysiol Haemost Thromb 2002, 32 (Suppl. 3): 23-28.
57. Yonekawa, Y., Handa, H., Okamoto, S. et al. Treatment of cerebral infarction in the acute stage with synthetic antithrombin MD-805: A multicenter clinical study. Nippon Geka Hokan 1986, 55: 711-26.
58. LaMonte, M.P. Argatroban in thrombotic stroke. Pathophysiol Haemost Thromb 2002, 32 (Suppl. 3): 39-45.
59. Kobayashi, S., Tazaki, Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 1997, 23: 531-4.
60. Maruki, Y., Onoda, A., Matsuzaki, M., Narabayashi, Y., Sawada, M., Shimazu, K. A specific thrombin inhibitor (argatroban) ameliorated cerebral blood flow in the patients with acute cerebral infarction. Keio J Med 2000, 49 (Suppl. 1): A138-A140.
61. LaMonte, M.P., Nash, M.L., Wang, D.Z. et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): A randomized, placebo-controlled safety study. Stroke 2004, 35: 1677-82.
62. Matsuo, T., Nakao, K., Yamada, T., Matsuo, O. Effect of a new anticoagulant (MD 805) on platelet activation in the hemodialysis circuit. Thromb Res 1986, 41: 33-41.
63. Ota, K., Akizawa, T., Hirasawa, Y., Agishi, T., Matsui, N. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 2003, 18: 1623-30.
64. Hara, T., Naito, K. Inherited antithrombin deficiency and end stage renal disease. Med Sci Monit 2005, 11: RA346-RA354.
65. Tang, I.Y., Cox, D.S., Patel, K. et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2005, 39: 231-6.
66. Warkentin, T.E. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 2004, 30: 273-83.
67. Warkentin, T.E., Kelton, J.G. Heparin and platelets. Hematol Oncol Clin N 1990, 4: 243-64.
68. Lewis, B.E., Wallis, D.E., Berkowitz, S.D. et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103: 1838-43.
69. Lewis, B.E., Wallis, D.E., Leya, F., Hursting, M. J., Kelton, J.G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003, 163: 1849-56.
70. Matthai, W.H. Jr. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost 1999, 25 (Suppl. 1): 57-60.
71. Lewis, B.E., Matthai, W.H. Jr., Cohen, M., Moses, J.W., Hursting, M.J., Leya, F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002, 57: 177-84.
72. LaMonte, M.P., Brown, P.M., Hursting, M.J. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004, 32: 976-80.
73. Harder, S., Graft, J., Klinkhardt, U. et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: Effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Thromb Haemost 2004, 91: 1137-45.
74. Herrman, J.P., Suryapranata, H., den Heijer, P., Gabriel, L., Kutryk, M.J., Serruys, P.W. Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study. J Thromb Thrombolysis 1996, 3: 367-75.
75. Hirahara, T., Kubo, N., Ohmura, N. et al. Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction. J Cardiol 2004, 44: 47-52.
76. Itoh, T., Nonogi, H., Miyazaki, S. et al. Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty: a prospective randomized pilot study. Circ J 2004, 68: 615-22.
77. Vermeer, F., Vahanian, A., Pels, P.W. et al. Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI Study. J Thromb Thrombolysis 2000, 10: 233-40.
78. Jang, I.K., Brown, D.F., Giugliano, R.P. et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial infarction with Novastan® and TPA (MINT) study. J Am Coll Cardiol 1999, 33: 1879-85.
79. Kawada, T., Mieda, T., Abe, H. et al. Left heart bypass with the bio-medicus centrifugal pump by the use of an antithrombin agent, argatroban. Kyobu Geka 1994, 47: 803-8.
80. Kawada, T., Okada, Y., Hoson, M. et al. Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture. Jpn J Thorac Cardiovasc Surg 1999, 47: 104-9.
81. Kawada, T., Kitagawa, H., Hoson, M., Okada, Y., Shiomura, J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 2000, 14: 445-57.
82. Jang, I.K., Lewis, B.E., Matthai, W.H. Jr., Kleiman, N.S. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: An open-label, nonrandomized pilot study. J Thromb Thrombolysis 2004, 18: 31-7.
83. Inglis, A.M., Sheth, S.B., Hursting, M.J., Tenero, D.M., Graham, A.M., DiCicco, R.A. Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin. Am J Health Syst Pharm 2002, 59: 1258-66.
84. Clarke, R.J., Mayo, G., FitzGerald, G.A., Fitzgerald, D.J. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991, 83: 1510-8.
85. Hursting, M.J., Lewis, B.E., Macfarlane, D.E. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2005, 11: 279-87.